First National Bank & Trust Co. of Newtown Cuts Stock Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

First National Bank & Trust Co. of Newtown trimmed its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 8.8% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,417 shares of the medical equipment provider’s stock after selling 234 shares during the period. First National Bank & Trust Co. of Newtown’s holdings in Zimmer Biomet were worth $261,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in ZBH. Crewe Advisors LLC purchased a new stake in shares of Zimmer Biomet during the 1st quarter valued at about $31,000. Bangor Savings Bank acquired a new position in Zimmer Biomet in the 3rd quarter worth $31,000. Family Firm Inc. purchased a new position in Zimmer Biomet in the 2nd quarter valued at about $33,000. J.Safra Asset Management Corp increased its position in shares of Zimmer Biomet by 712.1% during the first quarter. J.Safra Asset Management Corp now owns 268 shares of the medical equipment provider’s stock worth $35,000 after acquiring an additional 235 shares during the last quarter. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA acquired a new position in shares of Zimmer Biomet in the 2nd quarter valued at approximately $43,000. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Zimmer Biomet Stock Performance

ZBH opened at $108.69 on Friday. The business has a 50 day moving average price of $106.64 and a two-hundred day moving average price of $110.58. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.36 and a quick ratio of 0.70. The company has a market capitalization of $21.64 billion, a price-to-earnings ratio of 20.66, a price-to-earnings-growth ratio of 2.02 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a 1-year low of $101.47 and a 1-year high of $133.90.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share for the quarter, meeting the consensus estimate of $1.74. The business had revenue of $1.82 billion during the quarter, compared to analyst estimates of $1.80 billion. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The company’s revenue was up 4.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.65 earnings per share. Research analysts predict that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, October 31st. Investors of record on Monday, September 30th were issued a $0.24 dividend. The ex-dividend date of this dividend was Monday, September 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.88%. Zimmer Biomet’s payout ratio is currently 18.25%.

Analyst Upgrades and Downgrades

ZBH has been the subject of several research analyst reports. Wells Fargo & Company boosted their target price on shares of Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. Needham & Company LLC reiterated a “hold” rating on shares of Zimmer Biomet in a research report on Thursday, October 31st. Robert W. Baird reduced their price target on shares of Zimmer Biomet from $155.00 to $145.00 and set an “outperform” rating on the stock in a research report on Thursday, August 8th. Wolfe Research initiated coverage on shares of Zimmer Biomet in a research report on Tuesday, September 10th. They set a “peer perform” rating for the company. Finally, Evercore ISI cut their target price on shares of Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating on the stock in a report on Tuesday, October 1st. Two analysts have rated the stock with a sell rating, twelve have assigned a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $124.11.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.